Building a successful business requires people to pay for what you’re selling. In healthcare, those who pay are often insurers (both government and private) who need to approve your technology or associated procedure before they will pay for a healthcare provider to use it in a service.
Reimbursement is the process whereby a healthcare provider is paid for providing a service, and healthtech innovators need to consider any requirements for reimbursement (for example, demonstrating added value) or risk a lack of product uptake, even if safety and efficacy requirements are met.
The reimbursement landscape differs by country, and a reimbursement strategy for target markets should be considered early in development, as it impacts everything from research and development (R&D) and clinical studies to marketing plans and pitching to investors.
The US is an example of a multi-payer reimbursement landscape that’s more complex than that of NZ. Multiple public and private insurers provide coverage to most of the population. The Centers for Medicare and Medicaid Services (CMS) is the main public and largest single insurer in the US.
Healthcare providers use diagnosis-related groups and code sets for administration and billing purposes. The CMS provides an overview of codes here. As an example, CPT codes describe procedures and services, and are widely used by both public and private insurers. Read more from the American Medical Association here.
Considering CPT codes, a reimbursement strategy could include examining what existing codes may apply to a health technology for billing, or determining if a new code is needed, and what evidence would be required to gain adoption of the health technology (for example, clinical evidence and added value). You can read more about this case here.
The CPT example referenced above is a fee-for-service model, but it is not the only payment model in an evolving US reimbursement landscape. The American Hospital Association explores current and emerging payment models here.
You can read more about selling healthcare solutions in the US here covering resources put together by NZTE. Other helpful resources referenced in the HTA's November 2021 US medical device reimbursement tutorial are included in the table on the right, and you can read the HTA blog on the topic here. The recording of the tutorial is available on the HTA webinars page.
An area of ongoing development in healthtech reimbursement is the tools used to assist payers in decision making. These tools include the health technology assessment, which can be defined as ‘a multidisciplinary field that addresses the health impacts of technology, considering its specific healthcare context as well as available alternatives' - HTA International, 2013.
Health technology assessments are used by payers and other organisations in many countries, including in NZ and the US. For further reading, key examples from the UK and Australia are provided below.
For a discussion on healthtech reimbursement in the US versus Asia Pacific, see this webinar from the MedTech Innovator.
Many innovators will be targeting global healthcare markets with their technology. The links below contain information to help you gain a better understanding of reimbursement strategies and requirements offshore.
Browse more resources on our Articles & Reports page: